ConductScience.org, home

Trial · NCT04115293

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total ScorePlacebo-2.3095% Confidence Interval -3.17 to -1.43score on a scale
Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total ScoreZilucoplan 0.3 mg/kg-4.3995% Confidence Interval -5.28 to -3.50score on a scale
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Total ScorePlacebo-3.2595% Confidence Interval -4.32 to -2.17score on a scale
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Total ScoreZilucoplan 0.3 mg/kg-6.1995% Confidence Interval -7.29 to -5.08score on a scale
Change From Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Scale Total ScorePlacebo-5.4295% Confidence Interval -6.98 to -3.86score on a scale
Change From Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Scale Total ScoreZilucoplan 0.3 mg/kg-8.6295% Confidence Interval -10.22 to -7.01score on a scale
Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life Revised (MG-QoL15r) Scale Total ScorePlacebo-3.1695% Confidence Interval -4.65 to -1.67score on a scale
Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life Revised (MG-QoL15r) Scale Total ScoreZilucoplan 0.3 mg/kg-5.6595% Confidence Interval -7.17 to -4.12score on a scale
Time to First Receipt of Rescue Therapy Over the 12-week Treatment PeriodPlaceboNAFull Range NA to NADays
Time to First Receipt of Rescue Therapy Over the 12-week Treatment PeriodZilucoplan 0.3 mg/kgNAFull Range NA to NADays
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 12 Without Rescue TherapyPlacebo5.8percentage of participants
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 12 Without Rescue TherapyZilucoplan 0.3 mg/kg14.0percentage of participants
Percentage of Participants Achieving a ≥ 3-point Reduction in MG-ADL Score at Week 12 Without Rescue TherapyPlacebo46.1percentage of participants
Percentage of Participants Achieving a ≥ 3-point Reduction in MG-ADL Score at Week 12 Without Rescue TherapyZilucoplan 0.3 mg/kg73.1percentage of participants
Percentage of Participants Achieving a ≥5-point Reduction in QMG Score Without Rescue Therapy at Week 12Placebo33.0percentage of participants
Percentage of Participants Achieving a ≥5-point Reduction in QMG Score Without Rescue Therapy at Week 12Zilucoplan 0.3 mg/kg58.0percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Placebo70.5percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Zilucoplan 0.3 mg/kg76.7percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04115293/results